Why the study?
Cardiovascular risk increases as FINDRISC increases, but data are lacking for patients with a FINDRISC score of 12 or higher in Colombia.
Does a higher FINDRISC-C score correlate with increased cardiovascular risk in Colombian patients?
Does a higher FINDRISC-C score correlate with increased cardiovascular risk in Colombian patients?
Patients with a FINDRISC-C score ≥ 12 have a moderate to high cardiovascular risk, which increases as the score increases.
FINDRISC-C may aid risk identification in Colombian adults; leaves open prospective validation versus standard tools.
Introduction: the FINDRISC tool allows calculating the risk for developing diabetes, with a cutoff point of 12 for Colombia. There is evidence that cardiovascular risk (CVR) increases as this score increases, but there is no information when the value is ≥ 12 in Colombia. Objective: to establish CVR in patients with a FINDRISC-C of 12 or higher based on the adjusted Framingham risk score for Colombia. Materials and Methods: retrospective cross-sectional sub-analysis in which the FINDRISC-C questionnaire was administered to 796 patients, of which 293 had a score of 12 or higher and 262 met the eligibility criteria. CVR was calculated by univariate and multivariate analyses, statistic significances and multiple correspondence analysis. Results: of 262 patients, 63% women, 87% had overweight and obesity, average abdominal circumference was 97 cm, 10% smoked and 48% had a family history of type 2 diabetes mellitus. A CVR media of 8.10 (CI 7.29-8.91) was found, the mean score for each category when stratifying the FINDRISC-C was: moderate FINDRISC-C (7.83); high FINDRISC-C (7.87), very high FINDRISC-C (12.61). The prevalence of dyslipidemia was 46.2 % (CI 95%: 40-50), higher among men (53.6%). Conclusion: patients with a FINDRISC-C ≥ 12 have a moderate to high CVR. As the FINDRISC-C value increases, risk percentage, estimated on the basis of the adjusted Framingham risk score for Colombia, tends to increase. The prevalence of dyslipidemia among patients with FINDRISC-C ≥ 12 was elevated.
No takes yet. Share an insight, caveat, or question.
Santana et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: